Boardroom Alpha
Start trial
10-K primary document
PYXS · Annual Report (Form 10-K) · Filed March 23, 2026

Pyxis Oncology Inc — 10-K exhibit

pyxs-ex23_1.htm
Pyxis Oncology Inc on Boardroom Alpha
EX-23.1

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)
Registration Statement (Form S-8 No. 333-260441) pertaining to the Pyxis Oncology, Inc. 2019 Stock Plan, the Pyxis Oncology, Inc. 2021 Equity and Incentive Plan, and the Pyxis Oncology, Inc. 2021 Employee Stock Purchase Plan of Pyxis Oncology, Inc.,
(2)
Registration Statement (Form S-8 No. 333-263950) pertaining to the Pyxis Oncology, Inc. 2021 Equity and Incentive Plan of Pyxis Oncology, Inc.,
(3)
Registration Statement (Form S-8 No. 333-266005) pertaining to the Pyxis Oncology, Inc. 2022 Inducement Plan of Pyxis Oncology, Inc.,
(4)
Registration Statement (Form S-8 No. 333-270753) pertaining to the Pyxis Oncology, Inc. 2021 Equity and Incentive Plan and the Pyxis Oncology, Inc. 2021 Employee Stock Purchase Plan of Pyxis Oncology, Inc.,
(5)
Registration Statement (Form S-8 No. 333-274178) pertaining to the Apexigen, Inc. 2022 Equity Incentive Plan of Pyxis Oncology, Inc.,
(6)
Registration Statement (Form S-8 No. 333-272510) pertaining to the Apexigen, Inc. 2010 Equity Incentive Plan, the Apexigen, Inc. 2020 Equity Incentive Plan, and the Apexigen, Inc. 2022 Equity Incentive Plan of Pyxis Oncology, Inc.,
(7)
Registration Statement (Form S-8 No. 333-278159) pertaining to the Pyxis Oncology, Inc. 2021 Equity and Incentive Plan, the Pyxis Oncology, Inc. 2021 Employee Stock Purchase Plan, and the Apexigen, Inc. 2022 Equity Incentive Plan of Pyxis Oncology, Inc.,
(8)
Registration Statement (Form S-8 No. 333-283161) pertaining to the Pyxis Oncology, Inc. 2021 Equity and Incentive Plan of Pyxis Oncology, Inc.,
(9)
Registration Statement (Form S-3 No. 333-278282) of Pyxis Oncology, Inc.,
(10)
Registration Statement (Form S-8 No. 333- 285889) pertaining to the Pyxis Oncology, Inc. 2021 Equity and Incentive Plan, as amended and the Apexigen, Inc. 2022 Equity Incentive Plan of Pyxis Oncology, Inc., and
(11)
Registration Statement (Form S-3 No. 333-291801) of Pyxis Oncology, Inc.;

of our report dated March 23, 2026, with respect to the consolidated financial statements of Pyxis Oncology, Inc. included in this Annual Report (Form 10-K) of Pyxis Oncology, Inc. for the year ended December 31, 2025.

/s/ Ernst & Young LLP

Boston, Massachusetts

March 23, 2026

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer